Vertex Pharmaceuticals
VRTX
$8.38 (2.04%)
1D
1W
3M
1Y
5Y
ALL
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Zacks Investment Research • 11 hours ago • VRTX
Vertex (VRTX) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesThe Motley Fool • 1 day ago • VRTX
5 Reasons Vertex Pharmaceuticals Is a Screaming Buy on the DipZacks Investment Research • 1 day ago • VRTX
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives SalesSeeking Alpha • 2 days ago • VRTX
Vertex Pharmaceuticals, Inc. (VRTX) Q1 2024 Earnings Call TranscriptZacks Investment Research • 2 days ago • VRTX
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top EstimatesCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.